A subscription to JoVE is required to view this content. Sign in or start your free trial.

Method Article

A Protocol for Measuring Cue Reactivity in a Rat Model of Cocaine Use Disorder

10.5K views

⸱

DOI:

10.3791/55864

⸱

June 18th, 2018

 ,  ,  ,  ,  ,  , 

* These authors contributed equally

In This Article

Summary

Cue reactivity is conceptualized as sensitivity to cues linked with drug-taking experiences that contribute to craving and relapse in abstinent humans. Cue reactivity is modeled in rats by measuring attentional orientation toward drug-associated cues that results in appetitive approach behavior in a cue reactivity test following self-administration and forced abstinence.

Abstract

Cocaine use disorder (CUD) follows a trajectory of repetitive self-administration during which previously neutral stimuli gain incentive value. Cue reactivity, the sensitivity to cues previously linked with the drug-taking experience, plays a prominent role in human craving during abstinence. Cue reactivity can be assessed as the attentional orientation toward drug-associated cues that is measurable as appetitive approach behavior in both preclinical and human studies. Herein describes an assessment of cue reactivity in rats trained to self-administer cocaine. Cocaine self-administration is paired with the presentation of discrete cues that act as conditioned reinforcers (i.e., house light, stimulus light, infusion pump sounds). Following a period of abstinence, lever presses in the cocaine self-administration context accompanied by the discrete cues previously paired with cocaine infusion are measured as cue reactivity. This model is useful to explore neurobiological mechanisms underlying cue reactivity processes as well as to assess pharmacotherapies to suppress cue reactivity and therefore, modify relapse vulnerability. Advantages of the model include its translational relevance, and its face and predictive validities. The primary limitation of the model is that the cue reactivity task can only be performed infrequently and must only be used in short duration (e.g., 1 hour), otherwise rats will begin to extinguish the pairing of the discrete cues with the cocaine stimulus. The model is extendable to any positively reinforcing stimulus paired with discrete cues; though particularly applicable to drugs of abuse, this model may hold future applications in fields such as obesity, where palatable food rewards can act as positively reinforcing stimuli.

Introduction

Cocaine use disorder (CUD) follows a trajectory of repetitive self-administration during which previously neutral stimuli gain incentive value1. Cue reactivity is the sensitivity to cues previously linked with the drug-taking experience, and it plays a prominent role in human craving2,3,4,5. The risk of progression to CUD, as well as relapse during abstinence, is thought to be higher for individuals who express high sensitivity to drug-associated cues6,7. Both....

Access restricted. Please log in or start a trial to view this content.

Protocol

All animal manipulations are carried out in accordance with the Guide for the Care and Use of Laboratory Animals (2011) and with approval from the Institutional Animal Care and Use Committee.

1. Animals

  1. Acclimate male Sprague Dawley rats approximately 8-9 weeks of age (250-260 g) for a minimum of seven days in a colony room maintained at 21-23 °C and 45-50% humidity on a 12 h light-dark cycle (lights on 6:00-18:00 h).
  2. House rats two/cage and handle daily throughout the study. Provide food and water ad libitum in the home cage throughout all phases of the study.
    NOTE: Food restriction incre....

Access restricted. Please log in or start a trial to view this content.

Results

Results of a cocaine self-administration and abstinence experiment followed by a cue reactivity test from a previously published study57 are shown in Figure 1. The study timeline is depicted in Figure 1A.

Rats individually transition from FR1 to FR5 as they meet criteria. As operant conditioning proceeds in the cocaine-administering group, rats g.......

Access restricted. Please log in or start a trial to view this content.

Discussion

Exposure to drug-paired cues and physiological changes in response to these cues16 are associated with relapse,11,16 and the cocaine cue reactivity test employed above contingently presents cocaine-paired cues in the absence of drug; thus, drug-seeking behavior in the form of previously-active lever presses serves as a measure of relapse vulnerability. The cue reactivity protocol described herein is a preclinical means by which relaps.......

Access restricted. Please log in or start a trial to view this content.

Disclosures

The authors have no conflicts of interest to disclose.

Acknowledgements

All behavioral testing was performed in the University of Texas Medical Branch (UTMB) Rodent In Vivo Assessment (RIVA) Core, directed by Dr. Kelly Dineley and housed within the Center for Addiction Research, directed by Dr. Kathryn Cunningham. Support for this work came from the Peter F. McManus Charitable Trust, National Institute of Environmental Health Sciences Center for Environmental Toxicology at UTMB (T32ES007254), Institute for Translational Sciences at UTMB (UL1TR001439), Mitchell Center for Neurodegenerative Diseases, and Center for Addiction Research at UTMB (DA007287, DA070087, and pilot study funds).

....

Access restricted. Please log in or start a trial to view this content.

Materials

List of materials used in this article
NameCompanyCatalog NumberComments
Equipment
Catheter Tubing: 0.50mm ID x 0.94mm OD x 0.2mm widthFisher Scientific, Hampton, NH, USA11-189-15A1/experiment
Cue LightMed Associates Inc., St. Albans, VT, USAENV-229M2/operant chamber
Guide Cannulae (22 gauge, pedestal size-8mm, cut length 11 mm, 5 mm above the pedestal)Plastics One, Roanoke, VA, USA8IC313G5UPXC1/rat
House LightMed Associates Inc., St. Albans, VT, USAENV-227M1/operant chamber
Infusion PumpMed Associates Inc., St. Albans, VT, USAPHM-1001/operant chamber
LeversMed Associates Inc., St. Albans, VT, USAENV-110M2/operant chamber
Liquid SwivelsInstech, Plymouth Meeting, PA, USA375/221/operant chamber
MED-PC Package with Infusion Pump SoftwareMed Associates Inc., St. Albans, VT, USASOF-735 (infusions software SOF-700RA-10 version 1.04)1
Metal Spring LeashPlastics One, Roanoke, VA, USAC313CS/SPC1/operant chamber
Needle (23g, 1 in)Becton Dickinson, Franklin Lakes, NJ, USA3051931/operant chamber
Nitex Mesh (6/6 woven mesh sheet, 12"x12", 500 microns thick, 38% Open Area)Amazon, Seattle, WA, USACMN-0500-C, B000FMUNE6~1 sheet/100 rats
PCI Interface PackageMed Associates Inc., St. Albans, VT, USADIG-700P2-R2, MED-SYST-161/16 operant chambers
Power Supply for Interface ModulesMed Associates Inc., St. Albans, VT, USASG-6510D1/16 operant chambers
Sound-attenuating CubicleMed Associates Inc., St. Albans, VT, USAENV-018V1/operant chamber
Syringes, 10 mL Luer-Lok™ tipFisher Scientific, Hampton, NH, USA14-827-521 case/experiment (1/operant chamber)
Tygon Tubing for flushes: 0.51mmID x 1.52mm OD 0.51mm width x 152.4m lengthFisher Scientific, Hampton, NH, USA14-170-15B1/experiment
Chemicals
Acepromazine (10mg/mL)Henry Schein (Animal Health), Melville, NY, USA003845~0.5mg/rat*
Acraweld Repair ResinHenry Schein (Dental), Melville, NY, USA10139591/experiment
Altalube (ophthalmic ointment)Henry Schein (Dental), Melville, NY, USA60500591/experiment
CocaineNIDA North Bethesda, MD, USAN/A~350mgs/rat for whole experiment*; requires DEA License
Heparin (10,000 USP units/10 mL)Sagent Pharmaceuticals, Schaumburg, IL, USANDC 25021-400-101/experiment (~21 units/rat*)
Jet LiquidHenry Schein (Dental), Melville, NY, USA12564011/experiment
Ketamine (100mg/mL, 10mL)Henry Schein (Dental), Melville, NY, USA1049007~15mg/rat*; requieres DEA license
Methohexital Sodium (Brevital®, 500 mg/50 mL)Patterson Dental, Saint Paul, MN, USA043-54611/experiment; requires DEA License
Saline (0.9%, USP)Baxter, Deerfield, IL, USA2B13071 case/experiment
Streptokinase from β-hemolytic Streptococcus (Lancefield Group C) ≥3,000 units/mgSigma Aldrich, St. Louis, MO, USAS3134-250KU1 vial/experiment (~1.5mg/rat/experiment*)
Ticarcillin Disodium SaltFisher Scientific, Hampton, NH, USA50-213-695~4 vials/exeriment or purchase the 25g vial cat.# 50-489-093 (~150mg/rat/experiment*)
Xylazine (100mg/mL)Henry Schein (Animal Health), Melville, NY, USA033198~3mg/rat*
*Assumes rat age is that described in the protocol, rats self-administer for 14 days, and flushes occur for 21 days.

References

  1. Koob, G. F., Volkow, N. D. Neurobiology of addiction: a neurocircuitry analysis. Lancet Psychiatry. 3 (8), 760-773 (2016).
  2. Carter, B. L., Tiffany, S. T. Meta-analysis of cue-reactivity in addiction research. Addiction. 94 (3), 327-340 (1999).
  3. Drummond, D. C.

Access restricted. Please log in or start a trial to view this content.

Reprints and Permissions

Explore More Articles

Cocaine Self-AdministrationLever PressAbstinence PeriodCatheter PatencyFixed Ratio ScheduleOperant ChamberInfusion PumpRelapse Risk